ACE2-targeting protein conjugate coupled by RBD-Fc and tunicamycin and application of ACE2-targeting protein conjugate
Through the protein conjugate ADC-RBD coupled to tunicamycin, the treatment problems brought about by RBD region mutation and glycosylation modification of the new coronavirus were solved, and effective inhibition of the new coronavirus was achieved, and by reducing ACE2 Glycosylation, blocking viral invasion, provides an efficient targeted therapy solution.
Patent Information
- Application Number
- CN202411180821.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-27
- Publication Date
- 2024-11-29
AI Technical Summary
RBD regional mutation of the new coronavirus has led to the failure of existing drug treatment strategies, and the glycosylation modification of the virus has reduced its immunogenicity and infectivity. It is difficult for the existing technology to effectively inhibit the cell invasion of the new coronavirus.
ADC-RBD, a targeted ACE2 protein conjugate coupled to tumemycin, developed ADC-RBD, which can specifically target by connecting the RBD-Fc fusion protein with the N-glycosylation inhibitor tumemycin. ACE2 protein conjugate reduces the glycosylation of ACE2 on the cell surface, thereby inhibiting the infection of the new coronavirus.
This protein conjugate can effectively reduce the glycosylation of ACE2 on the cell surface, block the binding of the new coronavirus to the receptor, and inhibit the virus from invading cells. It provides a targeted therapeutic drug for N-glycosylation sites, with High affinity and easy-to-access reagent characteristics.
Smart Images

Figure HDA0005012103930000011 
Figure HDA0005012103930000012 
Figure HDA0005012103930000013
Abstract
Description
Technical Field
[0001] The present invention belongs to gene and antibody engineering, and relates to a protein conjugate targeting ACE2 coupled with RBD-Fc and tunicamycin. It is the synthesis of the protein conjugate ADC-RBD targeting human angiotensin converting enzyme 2 (ACE2) and the analysis of its antiviral effect, which shows the application prospect of ADC-RBD as a targeted therapeutic drug against the new coronavirus. Background Art
[0002] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can cause functional damage to multiple systems including the respiratory system, digestive system, cardiovascular system, renal system, immune system and nervous system. ACE2 is a type I membrane-bound glycoprotein and a key receptor that mediates SARS-CoV-2 entry into cells. The receptor binding domain (RBD) of the SARS-CoV-2 Spike protein is responsible for recognizing and binding to the receptor ACE2 on the surface of host cells, which is crucial in the invasion of the virus. The continuous mutation of the RBD region of the SARS-CoV-2 virus poses a challenge to existing drug treatment strategies, especially the changes in the structure and function of important immune regulatory proteins, which play a key role in viral evolution and immune escape response. Therefore, it is of great significance to propose a research strategy targeting the variability of the RBD region for the treatment of the new coronavirus.
[0003] The structural proteins of the new coronavirus (such as S, M and E proteins) are all glycosylated, which affects the assembly of the virus, host recognition and membrane fusion. Glycosylation can be mainly divided into N-glycosylation and O-glycosylation. N-glycans can only be attached to the side chains of asparagine residues with NXS / T sequence sites, and the first reaction is catalyzed by GlcNAc phosphotransferase (GPT). Once the polypeptide chain of the glycoprotein enters the endoplasmic reticulum and exposes the NXS / T sequence site, the oligosaccharide precursor can be transferred as a whole to the side chains of asparagine residues of the protein polypeptide chain under the action of glycotransferase and partially excised and modified, and the N-glycans are further processed in the Golgi apparatus. Studies have found that the S protein of SARS-CoV-2 has 22 N-glycosylation sites, and N354 glycosylation not only enhances the immune escape ability of the virus, but also reduces the immunogenicity of the virus and reduces the immune imprinting of the host. The loss of double glycosylation at the N331 and N343 sites can lead to a sharp decrease in viral infectivity by 1,200 times, indicating that N-glycosylation has a very important effect on its function. Secondly, the extracellular N-terminal region of ACE2 is highly N-glycosylated. The destruction of ACE2 glycosylation does not affect its expression on the cell surface or its binding to the SARS-CoV S-glycoprotein, but it will impair the ability of the virus to enter the cell, resulting in a reduction in the production of infectious viruses. Chloroquine and its alternative hydroxychloroquine can effectively inhibit SARS-CoV-2 infection in vitro by increasing the pH value of intracellular organelles and changing the glycosylation characteristics of ACE2 receptors, thereby interfering with host cell entry and subsequent viral replication. Obviously, the study of N-glycosylation is helpful in discovering therapeutic targets and drugs for coronaviruses and its importance in the development of potential new therapies. RBD protein can specifically recognize ACE2 protein, and after connecting with drugs that inhibit glycosylation to form protein-coupled drugs, it can reduce the glycosylation of ACE2 protein on the cell surface and reduce the affinity of ACE2 to RBD. At the same time, by inhibiting the glycosylation of S protein, the infection and replication of coronaviruses such as SARS-CoV and SARS-CoV-2 are inhibited. Summary of the invention
[0004] The purpose of the present invention is to provide a protein conjugate targeting ACE2 coupled with RBD-Fc and tunicamycin, which is a protein conjugate ADC-RBD coupled with RBD-Fc and tunicamycin targeting ACE2, wherein the RBD-Fc fusion protein and the N-glycosylation inhibitor tunicamycin (TM) are synthesized under certain conditions by a glutaraldehyde linker to form a protein conjugate drug ADC-RBD that can target ACE2. The fusion protein is then combined with the N-glycosylation inhibitor tunicamycin (TM) to synthesize a protein conjugate ADC-RBD that can target ACE2 under certain conditions. This protein conjugate can specifically target ACE2 protein, reduce the glycosylation of ACE2 on the cell surface, and thus inhibit the infection of cells by the new coronavirus.
[0005] The protein-coupled drug ADC-RBD of the present invention is prepared by the following steps: first, 2.4 mg TM is dissolved in 1 ml of anhydrous pyridine, followed by the addition of 0.9 mg of glutaric anhydride, and after dissolution, it is placed in a shaker at 37°C and 220 rpm for 24 hours. 4 ml of anhydrous ether is added to the solution, the synthesized product is precipitated, 5000 rpm, centrifuged for 3 minutes, the supernatant is discarded, and the anhydrous ether is washed twice. 100 μl of DMF is used to dissolve the precipitate, 2.4 mg of NHS and 1.2 mg of DCC are added to the solution at 37°C and 220 rpm for 24 hours. 4 ml of anhydrous ether is added to the solution, the synthesized product is precipitated as white crystals, 5000 rpm, centrifuged for 3 minutes, the supernatant is discarded, and the anhydrous ether is washed twice. 2 mg of RBD protein is added to react at 4°C for 16 hours, and the unreacted small molecules are ultrafiltered by a 10KDa ultrafiltration tube. SDS-PAGE protein gel and mass spectrometry are used to detect the synthesis.
[0006] Another object of the present invention is to provide the use of the protein conjugate in the preparation of a drug for inhibiting novel coronavirus cell infection. The conjugate can specifically target ACE2-positive host cells, inhibit the glycosylation of ACE2 on the surface of host cells and the glycosylation of S protein, block the binding of novel coronavirus to receptors, and thus inhibit the cell infection of novel coronavirus.
[0007] The present invention provides a conjugated drug targeting ACE2 conjugated with RBD-Fc and tunicamycin, in which the RBD protein in the protein conjugate can bind to the receptor ACE2, and tunicamycin is used as a small molecule drug to inhibit host protein glycosylation. The ACE2-targeted protein conjugate ADC-RBD is internalized into a cell line expressing ACE2, and the small molecule drug is released to inhibit glycosylation, reduce the glycosylation of ACE2 on the cell surface, and thus inhibit the infection of the new coronavirus to the cell. The protein conjugate ADC-RBD provided by the present invention can specifically bind to ACE2, enter the cell to inhibit glycosylation, block the binding of the new coronavirus to the receptor, and inhibit the invasion of the new coronavirus into the cell, and can be used for the development of targeted therapeutic drugs for N-glycosylation sites. The beneficial effects of the present invention are: (1) The reagents used in the present invention are simple and easy to obtain, low in price, and the protein conjugate prepared according to the new coronavirus receptor binding domain RBD has strong binding ability and high affinity; (3) The protein conjugate obtained by the present invention reduces the glycosylation of ACE2 on the cell surface, inhibits the binding of the virus to the cell, and blocks the infection of the new coronavirus to the cell. BRIEF DESCRIPTION OF THE DRAWINGS
[0008] Figure 1 It is a mass spectrometry analysis of ADC-RBD targeting ACE2 protein conjugate.
[0009] Figure 2 This is an analysis of the deglycosylation effect of ADC-RBD targeting ACE2 protein conjugate on HEK 293A-ACE2 cells.
[0010] Figure 3 This is an analysis of the inhibitory effect of ADC-RBD targeting ACE2 protein conjugate on HEK 293A-ACE2 and HEK 293-Spike cell fusion.
[0011] Figure 4 Analysis of the killing effect of ADC-RBD targeting ACE2 protein conjugate on Vero E6 cells ( Figure 4 A) and analysis of anti-SARS-CoV-2 virus infection effect ( Figure 4 B).
[0012] Figure 5 This is an analysis of the inhibitory effect of ADC-RBD targeting ACE2 protein on the killing of SARS-CoV-2 virus. DETAILED DESCRIPTION
[0013] The present invention is further described in conjunction with the following embodiments and drawings.
[0014] Example 1: Synthesis and mass spectrometry analysis of ADC-RBD targeting ACE2 protein conjugate
[0015] Experimental method: First, use 1ml of anhydrous pyridine to dissolve 2.4mg TM, then add 0.9mg glutaric anhydride, and put it in a shaker at 37℃ and 220rpm for 24h after dissolution. 4ml of anhydrous ether is added to the solution, the synthesized product is precipitated, 5000rpm, centrifuged for 3min, discarded the supernatant, and washed twice with anhydrous ether. 100μl DMF dissolves the precipitate, 2.4mg NHS and 1.2mg DCC are added to the shaker at 37℃ and 220rpm for 24h. 4ml of anhydrous ether is added to the solution, the synthesized product is precipitated as white crystals, 5000rpm, centrifuged for 3min, discarded the supernatant, and washed twice with anhydrous ether. Add 2mg RBD protein and react at 4℃ for 16h, and ultrafilter the unreacted small molecules with a 10KDa ultrafiltration tube. Mass spectrometry is used to detect the synthesis.
[0016] Experimental results: Mass spectrometry results showed that compared with the RBD-Fc protein, the protein peak of the protein conjugate shifted to the right, proving that the RBD-Fc protein was successfully connected to the TM ( Figure 1 ).
[0017] Example 2: Analysis of the deglycosylation effect of ADC-RBD targeting ACE2 protein conjugate on HEK 293A-ACE2 cells
[0018] Experimental method: HEK 293A-ACE2 cells were plated in six-well plates, with 1x 10 5 After overnight culture, different concentrations of protein conjugate ADC-RBD were added for 36 h or 2 μg / ml protein conjugate was added for different time periods, samples were collected, and Western Blot was used to analyze the effect of protein conjugate on ACE2 glycosylation in cells.
[0019] Experimental results: After treatment with protein conjugate ADC-RBD, the ACE2 glycosylation of cells was reduced and showed concentration and time dependence ( Figure 2 ).
[0020] Example 3: Analysis of the inhibitory effect of ADC-RBD targeting ACE2 protein conjugate on HEK 293A-ACE2 and HEK 293-Spike cell fusion
[0021] Experimental method: HEK 293A-ACE2 cells were plated in confocal culture dishes with an inoculation volume of 5 x 10 per well. 4 After 12 hours, add 0.06 μM ADC-RBD to the culture dish after the cells adhere to the wall, and continue to culture for 24 hours. Replace the fresh culture medium and add HEK 293-Spike cells to each dish. The inoculation volume is 2x 10 4cells. After 48 hours, the cell fusion was observed under a laser confocal microscope. Using a 20x objective lens, 5 fields of view were randomly selected, and the number of cell nuclei of cell fusion in each field of view was calculated, and graphs were drawn using Graphpad prime.
[0022] Experimental results: The Control group observed a more obvious cell fusion phenomenon, and the ADC-RBD group had a smaller number of cell fusions. Compared with the Control group, the ADC-RBD group inhibited cell fusion by 87% ( Figure 3 ).
[0023] Example 4: Analysis of the killing effect of ADC-RBD targeting ACE2 protein conjugate on Vero E6 cells and analysis of its anti-SARS-CoV-2 virus infection effect
[0024] Experimental method: Different concentrations of protein conjugate ADC-RBD were added to Vero E6 cells to detect the killing effect on cells, and the CCK8 method was used to determine the cell survival rate. Different concentrations of protein conjugate ADC-RBD were added to Vero E6 cells and pre-incubated for 6 hours, followed by the addition of 100 TCID50 of the new coronavirus and cultured at 37 degrees. After 72 hours, the cell supernatant was selected and its viral load was detected.
[0025] Experimental results: ADC-RBD had no obvious toxic side effects on E6 cells at a concentration of 0-8nM, and CC 50 56.43nM( Figure 4 A); ADC-RBD can significantly inhibit viral replication at a concentration of 2 nM, EC 50 0.11nM( Figure 4 B).
[0026] Example 5: Analysis of the inhibitory effect of ADC-RBD targeting ACE2 protein conjugate on SARS-CoV-2 virus killing
[0027] Experimental method: Different concentrations of protein conjugate ADC-RBD were added to Vero E6 cells and pre-incubated for 6 hours, then 100 TCID50 of the new coronavirus was added and cultured at 37 degrees. After 72 hours, the cell field of view was selected for photography.
[0028] Experimental results: ADC-RBD at 4 and 8 nM concentrations can significantly inhibit the killing effect of the virus on cells, and the cell viability suppressed by the virus is restored ( Figure 5 ).
[0029] For ordinary technicians in this field, the specific embodiments are only illustrative descriptions of the present invention. It is obvious that the specific implementation of the present invention is not limited to the above-mentioned methods. As long as various non-substantial improvements are made using the method concepts and technical solutions of the present invention, or the concepts and technical solutions of the present invention are directly applied to other occasions without improvement, they are all within the protection scope of the present invention.
Claims
1. A protein conjugate targeting ACE2 conjugated with RBD-Fc and tunicamycin, characterized in that: The conjugate is synthesized by combining RBD-Fc fusion protein and N-glycosylation inhibitor tunicamycin via a glutaraldehyde linker to obtain a protein conjugate ADC-RBD targeting ACE2.
2. The protein conjugate according to claim 1, characterized in that The preparation was achieved through the following steps: first, 2.4 mg TM was dissolved in 1 ml of anhydrous pyridine, and then 0.9 mg glutaric anhydride was added. After dissolution, the mixture was placed in a shaker at 37°C and 220 rpm for 24 h; 4 ml of anhydrous ether was added to the solution, the synthesized product was precipitated, centrifuged at 5000 rpm for 3 min, the supernatant was discarded, and the mixture was washed twice with anhydrous ether; 100 μl of DMF was used to dissolve the precipitate, 2.4 mg NHS and 1.2 mg DCC were added and the mixture was placed in a shaker at 37°C and 220 rpm for 24 h; 4 ml of anhydrous ether was added to the solution, the synthesized product was precipitated as white crystals, centrifuged at 5000 rpm for 3 min, the supernatant was discarded, and the mixture was washed twice with anhydrous ether; 2 mg of RBD protein was added to react at 4°C for 16 h, and unreacted small molecules were removed by ultrafiltration using a 10 KDa ultrafiltration tube to obtain a protein conjugate ADC-RBD.
3. Use of the protein conjugate according to claim 1 in the preparation of drugs for inhibiting infection of new coronavirus cells.
4. The use according to claim 3, characterized in that: The application is that the protein conjugate specifically targets ACE2-positive host cells and inhibits the glycosylation of ACE2 on the surface of the host cells and the glycosylation of the S protein, thereby blocking the binding of the new coronavirus to the receptor, inhibiting the invasion of the new coronavirus into cells, and thus inhibiting the infection of new coronavirus cells.
